Lebsanan

Tacrolimus, the active ingredient in Lebsanan, is a calcineurin inhibitor presented as a topical formulation for skin use. It is prescribed to manage inflammatory skin conditions such as atopic dermatitis and eczema. GNH USA supplies Lebsanan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lebsanan (tacrolimus) acts on the immune pathways that drive inflammatory skin disease. - Atopic dermatitis: reduces inflammation and pruritus, improving skin barrier function. - Eczema: decreases cytokine release, leading to clearer lesions and less itching. - Other inflammatory skin conditions: may alleviate symptoms by suppressing local immune activation.

Topical tacrolimus can cause local skin reactions, most of which are mild and reversible.

Common Side Effects: - Burning sensation: transient warmth at the application site. - Itching: mild pruritus may occur after use. - Redness: localized erythema. - Stinging: brief discomfort during application. - Dryness: skin may feel less hydrated. - Irritation: mild rash or discomfort.

Serious or Rare Side Effects: - Skin infection: secondary bacterial or fungal infection. - Allergic reaction: swelling, hives, or severe rash. - Eczema herpeticum: viral infection of compromised skin. - Systemic absorption: rare immunosuppression with extensive use. - Malignancy risk: theoretical increased skin cancer risk with long‑term use. - Severe burning: persistent intense pain requiring medical review.

Use Lebsanan only under medical supervision and follow prescribed instructions. - Assess severity: evaluate skin condition before initiating therapy. - Avoid infected skin: do not apply to open wounds or active infections. - Monitor systemic exposure: limit use on large body surface areas. - Use sparingly: apply a thin layer to the affected area. - Avoid occlusion: do not cover with airtight dressings unless directed. - Store at room temperature: keep in the original container, protect from moisture and light.

Tacrolimus topical may interact with other agents that affect skin integrity or systemic immunosuppression.

Major Interactions (Avoid): - Systemic tacrolimus: concurrent use can increase systemic exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise tacrolimus levels. - Live vaccines: immunosuppression may reduce vaccine efficacy. - Other potent immunosuppressants: additive immunosuppressive effect. - Phototherapy: may increase skin irritation.

Moderate Interactions (Monitor Closely): - Topical antibiotics: monitor for combined irritation. - Topical steroids: assess for additive skin thinning. - Antifungal creams: watch for local irritation. - Herbal skin products: potential for unpredictable reactions. - Vitamin A derivatives: may increase dryness.